Advanced Filters
noise
Found 1,843 clinical trials
L Liang Zhao

PET/CT for Trop2 ADC Response Evaluation NSCLC

To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in NSCLC patients.

18 years of age All Phase N/A
S Sung-Liang Yu, PhD

Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation

Liquid biopsy plays a pivotal role in cancer therapeutics, encompassing critical applications such as early cancer detection, disease progression monitoring, and tailored treatment plan formulation, heralded as a pivotal avenue for the future of cancer management. Established in 2015, LifeOS Genomics Co., Ltd. stands among the select few domestic enterprises …

18 years of age All Phase N/A
X Xiaomin Niu

Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations

Lung cancer is the most common primary cancer of the lung and is responsible for the ever increasing number of cancer-related deaths worldwide. Especially in China, the burden of lung cancer has been rising rapidly due to its large and growing population. Histologically, approximately 85% of lung cancers are non-small-cell …

18 years of age All Phase N/A
X Xueqin Yang, PH.D.

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC

Investigators established the efficacy evaluation criteria for tumor markers (RecistTM) in the preliminary research. Among patients with advanced non-small cell lung cancer, patients with positive driving genes are more likely to exhibit abnormalities in tumor markers, which suggests that this criteria may be more suitable for evaluating the efficacy of …

18 years of age All Phase N/A
N Nikki Denmark

Development and Analysis of a Stool Bank for Cancer Patients

This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunotherapies. Although animal models are of use to determine the influences of gut and other microbiota on cancer treatment modalities, they are …

18 years of age All Phase N/A
J Jialei Pro. Wang

Study on the Mechanism of Acquired Resistance of Entrectinib

The goal of this observational study is to learn about the mechanism of acquired resistance in first line trearment of ROS1-positive NSCLC with entrectinib. The main question it aims to answer is: what is the acquired resistant mechanism of entrectinib as first line treatment setting in patients? Tissue or blood …

18 years of age All Phase N/A
L Liu Huang

Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing

To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.

18 years of age All Phase N/A
F Feng Wang

99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors

At present, radiopharmaceuticals targeting FAP have been developed for the diagnosis and treatment of various tumors. Considering the problems of fast tumor tissue clearance and short retention time in small molecule FAP inhibitors based on quinoline rings, this project optimized their ligands and developed a new FAP targeted technetium labeled …

18 - 75 years of age All Phase N/A
R Rongrong Zhou

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

This is a prospective, single-center observational clinical study aimed at the efficacy and safety of radiotherapy combined with PD-1 inhibitors and chemotherapy in the treatment of Chinese patients with symptomatic NSCLC with brain metastases.

18 years of age All Phase N/A
F Feng Wang

18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis

Evaluate the safety of the novel FAP targeted molecular probe 18F-FAPI-YQ104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.

18 - 75 years of age All Phase N/A

Simplify language using AI